Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/18/21 (What's New)

Summary

  • Switches to 3-drug INSTI-based regimens have been favored in recent years due to:
    • High efficacy and tolerability, both as first-line regimens and switch regimens
    • High patient satisfaction following switch
    • Switching to Dolutegravir-Based 3-Drug Regimens
      Switching to Bictegravir/Emtricitabine/Tenofovir AF
        Switching to Raltegravir-Based 3-Drug Regimens

        Action required

        Keywords: Switch Strategies

        ©2020 Clinical Care Options, LLC. All Rights Reserved.

        The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.